UroGen Pharma (URGN) EBITDA (2017 - 2026)
UroGen Pharma's (URGN) quarterly EBITDA came in at -$20.3 million in Q1 2026, up 45.11% YoY from -$14.0 million in Q1 2025, and down 6.01% on a QoQ basis from -$19.1 million in Q4 2025.
UroGen Pharma (URGN) EBITDA (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of EBITDA data on file, last reported at -$20.3 million in Q1 2026.
- Quarterly EBITDA rose 45.11% year-over-year to -$20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.2 million (changed 0.24% YoY) and the FY2025 annual result came in at -$124.9 million, down 29.01% from the prior year.
- EBITDA fell to -$20.3 million in Q1 2026, from -$19.1 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$13.5 million in Q3 2023 to a low of -$41.4 million in Q2 2025.
- A 5-year average of -$22.7 million and a median of -$20.3 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA slumped 89.32% — and 2026, when it surged 45.11%.
- Tracing URGN's EBITDA over 5 years: stood at -$20.3 million in 2022, then grew by 27.97% to -$14.6 million in 2023, then slumped by 89.32% to -$27.7 million in 2024, then surged by 30.89% to -$19.1 million in 2025, then declined by 6.01% to -$20.3 million in 2026.
- The last three EBITDA figures came in at -$20.3 million (Q1 2026), -$19.1 million (Q4 2025), and -$27.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 111,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 111,000.00 |
| Mar 31, 2026 | -20.26 Mn |
| Dec 31, 2025 | -19.12 Mn |
| Sep 30, 2025 | -27.39 Mn |
| Jun 30, 2025 | -41.45 Mn |
| Mar 31, 2025 | -36.91 Mn |
| Dec 31, 2024 | -27.66 Mn |
| Sep 30, 2024 | -17.55 Mn |
| Jun 30, 2024 | -25.84 Mn |
| Mar 31, 2024 | -25.74 Mn |
| Dec 31, 2023 | -14.61 Mn |
| Sep 30, 2023 | -13.50 Mn |
| Jun 30, 2023 | -15.38 Mn |
| Mar 31, 2023 | -22.05 Mn |
| Dec 31, 2022 | -20.28 Mn |
| Sep 30, 2022 | -18.09 Mn |
| Jun 30, 2022 | -18.72 Mn |
| Mar 31, 2022 | -21.96 Mn |
| Dec 31, 2021 | -19.92 Mn |
| Sep 30, 2021 | -23.44 Mn |